Disease × agent evidence record

Tocilizumab for Long COVID / Post-Acute COVID Sequelae (PACVS): evidence, trials and status

Synthesis-level literature links Tocilizumab to Long COVID / Post-Acute COVID Sequelae (PACVS), but no registered trial in this database tests the pair, so the evidence is observational, pooled from other indications, or pre-dates registry practice.

0 registered trials 0 recruiting 14 publications Evidence tier A · Strong Score 50.0
Research Tracker › Pairs › Long COVID / Post-Acute COVID Sequelae (PACVS) › Tocilizumab
Research map, not treatment advice. This page aggregates registry and literature records. It does not evaluate efficacy, dosing or safety for any individual. Discuss any treatment decision with a qualified clinician.

Summary

Tocilizumab has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Long COVID / Post-Acute COVID Sequelae (PACVS) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Long COVID / Post-Acute COVID Sequelae (PACVS). No registered clinical trial in this database tests Tocilizumab specifically in Long COVID / Post-Acute COVID Sequelae (PACVS). The evidence below comes from published literature only, so any clinical signal has not yet been tested prospectively against this condition in a registered study. The literature layer holds 14 publications for this pair: 5 Cochrane reviews, 2 meta-analyses, 1 systematic review, 1 randomised controlled trial publication and 5 clinical trial publications. Publication years run from 2024 to 2026. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.

The RepurpOS disease-intelligence file for Post-Acute COVID/Vaccination Syndrome ranks 675 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Spontaneous resolution at 12 months: ~50-70% of patients; persistent symptoms at 2 years in 30-50%; severely debilitating long COVID in 10-15% at 1 year without intervention.

Open in Repurposing ExplorerLong COVID / Post-Acute COVID Sequelae (PACVS) hubLong COVID / Post-Acute COVID Sequelae (PACVS) biomarkers & interventionsChEMBLOpen Targets

Evidence table

Evidence tierA · Strong
Evidence score50.0 (trials 0.0, literature 30.0, tier 15, approved bonus 5.0)
Registered trials0 total: 0 recruiting, 0 active / not yet recruiting, 0 completed, 0 other
Linked publications14 (5 Cochrane reviews, 5 clinical trial publications, 2 meta-analyses, 1 systematic review, 1 randomised controlled trial publication)
Agent typeBiologic
Development stage (any indication)Approved
Mechanism / classNot recorded
Data sourcesOpen Targets, ChEMBL
How the evidence score is calculated
  • Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
  • Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
  • The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
  • Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
  • The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.

Registered clinical trials

No registered trial links Tocilizumab to Long COVID / Post-Acute COVID Sequelae (PACVS) in the current OSMF trial extract.

Search ClinicalTrials.gov for newer studies

Published literature

Run the live PubMed search

Mechanism and notes

No mechanism of action is recorded for this pair in the source databases.

OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.

Frequently asked questions

Is Tocilizumab approved for Long COVID / Post-Acute COVID Sequelae (PACVS)?

Tocilizumab has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Long COVID / Post-Acute COVID Sequelae (PACVS) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Long COVID / Post-Acute COVID Sequelae (PACVS). Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.

Is Tocilizumab in clinical trials for Long COVID / Post-Acute COVID Sequelae (PACVS)?

No registered clinical trial in this database tests Tocilizumab specifically in Long COVID / Post-Acute COVID Sequelae (PACVS). The evidence below comes from published literature only, so any clinical signal has not yet been tested prospectively against this condition in a registered study.

What does the evidence show for Tocilizumab in Long COVID / Post-Acute COVID Sequelae (PACVS)?

Synthesis-level literature links Tocilizumab to Long COVID / Post-Acute COVID Sequelae (PACVS), but no registered trial in this database tests the pair, so the evidence is observational, pooled from other indications, or pre-dates registry practice. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.

Cite this page

Open Source Medicine Foundation. Tocilizumab for Long COVID / Post-Acute COVID Sequelae (PACVS): evidence, trials and status. OSMF Research Tracker. Updated 2026-07-05. https://research.opensourcemed.info/pairs/post-acute-covidvaccination-syndrome/tocilizumab.html

Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.

Get OSMF research updates on Substack

This is a research map, not treatment advice. Evidence tiers and scores summarise what has been studied, not whether a treatment works or is safe for you.